p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma

Cancer Biology and Therapy

Volumn 1, Issue 5, 2002, Pages 511-517

  Sood, Anil K ^a   Coffin, Jeremy ^b   Jabbari, Sarvenaz ^b   Buller, Richard E ^b   Hendrix, Mary J C ^b   Klingelhutz, Al ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Ovarian cancer; p53; Telomerase

Indexed keywords

DNA BINDING PROTEIN; PROTEIN P53; RNA; TELOMERASE; TELOMERASE RNA;

AMINO ACID SEQUENCE; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOMA; CELL CULTURE; CHEMISTRY; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; MUTATION; OVARY TUMOR; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; CARCINOMA; DNA-BINDING PROTEINS; ENZYME ACTIVATION; FEMALE; GENES, P53; HUMANS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TELOMERASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85047686713     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.1.5.167     Document Type: Article

References (50)

1. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human Telomerase activity with immortal cells and cancer. Science 1994; 266:2011-5.
2. Kyo S, Kanaya T, Ishikawa H, Ueno H, Inoue M. Telomerase activity in gynecological tumors. Clin Cancer Res 1996; 2:2023-8. (Pubitemid 27006635)
3. Shay JW, Bacchetti SA. Survey of Telomerase activity in human cancer. Eur J Cancer 1997; 33:787-91.
4. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express Telomerase activity. EMBO J 1992; 11:1921-9.
5. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994, 91:2900-4. (Pubitemid 24130141)
6. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43:405-13. (Pubitemid 16213265)
7. Park TW, Riethdorf S, Riethdorf L, Loning T, Janicke F. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors. Int J Cancer 1999; 84:426-31. (Pubitemid 29337132)
8. Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, Hoffman AR. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer 2000; 85:330-5. (Pubitemid 30030404)
9. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3:1271-4. (Pubitemid 27508830)
10. Rohde V, Sattler H-P, Bund T, Bonkhoff H, fixemer T, Bachmann Cet al. Expression of the human Telomerase reverse transcriptase is not related to Telomerase activity in normal and malignant renal tissue. Clin Cancer Res 2000; 6:4803-9.
11. Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998; 19:182-6. (Pubitemid 28248803)
12. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90:785-95. (Pubitemid 27357969)
13. Ramakrishnan S, Eppenberger U, Mueller H, Shinaki Y, Narayanan R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 1998; 58:622-5. (Pubitemid 28099468)
14. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15:50-65. (Pubitemid 32060682)
15. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464-8. (Pubitemid 29361801)
16. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000; 89:2006-17.
17. Skilling JS, Sood AK, Neiman T, Lager DJ, Buller RE. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996; 13:117-23. (Pubitemid 26248551)
18. Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE. Distant metastases in ovarian cancer: Association with p53 mutations. Clin Cancer Res 1999; 5:2485-90. (Pubitemid 29437332)
19. Hanahan D. Benefits of bad telomeres. Nature 2000; 406:573-4. (Pubitemid 30641027)
20. Chin L, Artandi SE, Shen Q, Tam A, Lee S, Gottlieb GJ, et al. P53 deficiency rescues the adverse effects of telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97:527-53.
21. Brown T, Aldous W, Lance R, Blaser J, Baker T, Williard W. The association between telomerase, p53, and clinical staging in colorectal cancer. Am J Surg 1998; 175:364-6. (Pubitemid 28213445)
22. Harada K, Kurisu K, Tahara H, Tahara E, Ide T, Tahara E. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular marker. J Neurosurg 2000; 93:618-25. (Pubitemid 32799296)
23. Maniwa Y, Yoshimura M, Obayashi C, Inaba M, Kiyooka K, Kanki M, et al. Association of p53 gene mutation and telomerase activity in respectable non-small cell lung cancer. Chest 2001, 120:589-94. (Pubitemid 32881280)
24. Roos G, Nilsson P, Cajander S, Nielsen N-H, Arnerlov C, Landberg G. Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer. Int J Cancer 1998; 79:343-8. (Pubitemid 28359730)
25. Wu X, Kemp B, Amos CI, Honn SE, Zhang W, Walsh GL, et al. Associations among telomerase activity, p53 protein overexpression, and genetic instability in lung cancer. Br J Cancer 1999, 80:453-7. (Pubitemid 29213200)
26. Skilling J, Squatrito RC, Connor JP, Niemann T, Buller RE. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol Oncol 1996, 60:72-80. (Pubitemid 26028460)
27. Sood AK, Seftor EA, Fletcher M, Gardner LMG, Heidger PM, Buller RE, et al. Molecular determinants of ovarian cancer plasticity. American Journal of Pathology 2001; 158:1279-88. (Pubitemid 32281292)
28. Sood AK, Buller RE. SSCP and sequence analysis of p53 mutation in ovarian tumors. Methods in Molecular Medicine: Ovarian Cancer Methods and Protocols, 2000; 323-328. Bartlett JMS, ed. Humana Press, New Jersey.
29. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10(19):2438-51. (Pubitemid 26341879)
30. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor- DNA complex: understanding tumorigenic mutations. Science 1994; 265:346-55. (Pubitemid 24259959)
31. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, et al. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 1994, 265:386-91. (Pubitemid 24259970)
32. Soussi T, May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J Mol Biol 1996; 260:623-37. (Pubitemid 26270957)
33. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78. (Pubitemid 24289415)
34. Kass-Eisler A, Greider CW. Recombination in telomere-length maintenance. Trends Biochem Sci 2000; 24:200-4. (Pubitemid 30195838)
35. Reddel RR, Bryan TM, Murnane JP. Immortalized cells with no detectable telomerase activity. A review. Biochemistry 1997; 62:1254-62. (Pubitemid 127665914)
36. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60:6788-93. (Pubitemid 32059139)
37. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91:325-34. (Pubitemid 27467963)
38. Li H, Cao Y, Berndt MC, Funder JW, Liu J-P. Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro. Oncogene 1999; 18:6785-94.
39. Mekeel KL, Tang W, Kachnic LA, Luo CM, DeFrank JS, Powell SN. Inactivation of p53 results in high rates of homologous recombination. Oncogene 1997; 14:1847-57. (Pubitemid 27207686)
40. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70:937-48.
41. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999; 59:4175-9. (Pubitemid 29418720)
42. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406:641-5. (Pubitemid 30641052)
43. Kucherlapati R, DePinho RA. Telomerase meets its mismatch. Nature 2001; 411:647-648.
44. Rizki A, Lundblad V. Defects in mismatch repair promote telomerase-independent proliferation. Nature 2001; 411:713-6. (Pubitemid 32531679)
45. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260:812-6. (Pubitemid 23167611)
46. Peltomaki, P, Aaltonen, LA, Sistonen, P, Pylkkanen, L, Mecklin, JP, Jarvinen, H et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science; 1993, 260:810-12.
47. Thibodeau, SN, Bren, G, and Schaid, DJ. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816-9. (Pubitemid 23167612)
48. Sood AK, Holmes RW, Hendrix MJC, Buller RE. Application of the NCI international criteria for determination of microsatellite instability in ovarian cancer. Cancer Research 2001; 61:4371-4. (Pubitemid 32685761)
49. Kyo S, Kanaya T, Takakura M, Tanaka M, Yamashita A, Inoue H, et al. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors. Int J Cancer 1999; 80:804-9. (Pubitemid 29108852)
50. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5:1164-70. (Pubitemid 29474421)